Study comparing Platelet Rich Plasma with THBG in patients of melasma

Phase 3

Not yet recruiting

Conditions: Other disorders of the skin and subcutaneous tissue,

Registration Number: CTRI/2019/07/020435

Lead Sponsor: Government medical college bhavnagar

Brief Summary: Melasma is the most common cause of facial melanosis and is manifested by hyperpigmented macules on the face which become more pronounced after sun exposure

Transforming growth factor Beta 1(TGF B1) is present in Alfa granules of platelets

It is known to decrease melanogenesis via delayed extracellular signal-regulated kinase activation

Thba

Controls NF-kB pathway

Reduces PGE2 expression

Prevents melanin transfer to keratinocytes

Inhibits Tyrosinase

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 60

Inclusion Criteria

patients with age above 18 years irrespective of their sex clinically diagnosed melasma will be included in study .

Exclusion Criteria

Females on oral contraceptive pill Age <18 years Pregnant female Tendency for keloid, hypertrophic scar Bleeding disorder Platelet abnormality On anticoagulant drugs Chronic liver disease On oral tretinoin Refusal to allow photographs hiv/hbsag +ve.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Physician global assessment scale	after 6 weeks
MelasQOL(melasma quality of life)	after 6 weeks
dermoscope	after 6 weeks
Modified melasma area severity index	after 6 weeks
Patients global assessment scale	after 6 weeks

Secondary Outcome Measures

Name	Time	Method
dermoscopic and woods lamp dignosis of melasma	improvement in masi and melaqol

Trial Locations

Locations (1): sir t hospital
🇮🇳
Bhavnagar, GUJARAT, India
sir t hospital
🇮🇳Bhavnagar, GUJARAT, India
MilanJhavar
Principal investigator
9998534301
jhavarmilan@yahoo.in